SMARCB1 and atypical teratoid rhabdoid tumor: Diagnosis integrates clinical evaluation (including detailed family history), immunohistochemistry demonstrating loss of SMARCB1 or SMARCA4 protein expression, and tumor sequencing for somatic alterations; germline testing for pathogenic variants in SMARCB1 or SMARCA4 is recommended for all patients with ATRT.